These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28232728)

  • 41. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
    Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Whole-genome sequencing: a step closer to personalized medicine.
    Pasche B; Absher D
    JAMA; 2011 Apr; 305(15):1596-7. PubMed ID: 21505140
    [No Abstract]   [Full Text] [Related]  

  • 43. Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation?
    Yoon JH; Kim HJ; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):80-8. PubMed ID: 24149098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Precision oncology for acute myeloid leukemia using a knowledge bank approach.
    Gerstung M; Papaemmanuil E; Martincorena I; Bullinger L; Gaidzik VI; Paschka P; Heuser M; Thol F; Bolli N; Ganly P; Ganser A; McDermott U; Döhner K; Schlenk RF; Döhner H; Campbell PJ
    Nat Genet; 2017 Mar; 49(3):332-340. PubMed ID: 28092685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission.
    Lee YJ; Baek DW; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Kim HJ; Ham JY; Suh JS; Sohn SK; Moon JH
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e529-e535. PubMed ID: 30268640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission.
    Godwin CD; Fromm JR; Othus M; Sandmaier BM; Mielcarek MB; Wood BL; Appelbaum FR; Storb R; Walter RB
    Bone Marrow Transplant; 2019 Sep; 54(9):1511-1514. PubMed ID: 30804488
    [No Abstract]   [Full Text] [Related]  

  • 48. A "body armor" of leukemia cutis.
    Janssen NA; Hebeda KM; Stevens WB; van der Velden WJ
    Am J Hematol; 2015 Aug; 90(8):751. PubMed ID: 25611338
    [No Abstract]   [Full Text] [Related]  

  • 49. Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.
    Walter RB; Sandmaier BM; Storer BE; Godwin CD; Buckley SA; Pagel JM; Sorror ML; Deeg HJ; Storb R; Appelbaum FR
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):373-8. PubMed ID: 25278455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.
    Stelljes M; Beelen DW; Braess J; Sauerland MC; Heinecke A; Berning B; Kolb HJ; Holler E; Schwerdtfeger R; Arnold R; Spiekermann K; Müller-Tidow C; Serve HL; Silling G; Hiddemann W; Berdel WE; Büchner T; Kienast J;
    Haematologica; 2011 Jul; 96(7):972-9. PubMed ID: 21459795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
    De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
    Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hematopoietic cell transplantation in first complete remission versus early relapse.
    Appelbaum FR; Pearce SF
    Best Pract Res Clin Haematol; 2006; 19(2):333-9. PubMed ID: 16516131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Excellent Survival Outcomes of Pediatric Patients With Acute Myeloid Leukemia Treated With the MASPORE 2006 Protocol.
    Sutiman N; Nwe MS; Ni Lai EE; Lee DK; Chan MY; Eng-Juh Yeoh A; Soh SY; Leung W; Tan AM
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e290-e300. PubMed ID: 33384264
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey.
    Burke MJ; Burns L; Linden MA; Lindgren B; Verneris MR; Weisdorf D; Ustun C
    Am J Hematol; 2013 Sep; 88(9):826-7. PubMed ID: 23737091
    [No Abstract]   [Full Text] [Related]  

  • 55. Research on the clinical effect and in vitro study of HLA-mismatched hematopoietic stem cell infusion for acute myeloid leukemia.
    Zhang R; Zhao F; Wang J
    Hematology; 2015 Dec; 20(10):555-60. PubMed ID: 26067370
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
    Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AML and the art of remission maintenance.
    de Lima M; Roboz GJ; Platzbecker U; Craddock C; Ossenkoppele G
    Blood Rev; 2021 Sep; 49():100829. PubMed ID: 33832807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia.
    Tomizawa D; Tanaka S; Kondo T; Hashii Y; Arai Y; Kudo K; Taga T; Fukuda T; Goto H; Inagaki J; Koh K; Ohashi K; Ozawa Y; Inoue M; Kato K; Tanaka J; Atsuta Y; Adachi S; Ishida H
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1515-1522. PubMed ID: 28501543
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognosis of patients with core binding factor acute myeloid leukemia after first relapse.
    Kurosawa S; Miyawaki S; Yamaguchi T; Kanamori H; Sakura T; Moriuchi Y; Sano F; Kobayashi T; Yasumoto A; Hatanaka K; Yanada M; Nawa Y; Takeuchi J; Nakamura Y; Fujisawa S; Shibayama H; Miura I; Fukuda T
    Haematologica; 2013 Oct; 98(10):1525-31. PubMed ID: 23716553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.